Type 1 Diabetes
Conditions
Keywords
autoimmune disease, diabetes type 1, incretin effect
Brief summary
Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes
Detailed description
Assessment of immunological effects of Saxagliptin and Liraglutide on immune cells of the peripheral blood.
Interventions
DRUGLiraglutide
once daily subcutaneous injection
DRUGSaxagliptin
once daily tablet
Sponsors
Medical University of Graz
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
-healthy subjects or patients with type 1 diabetes
Exclusion criteria
* pregnancy * treatment with GLP-1-Analoga (Liraglutide, Exenatide) * treatment with DPP4-inhibitor (Sitagliptin, Vildagliptin, Saxagliptin) * chronic disease including a long-term medication over 4 weeks per year (except type 1 diabetes)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Increase of regulatory FOXP3+ T cells | 4 weeks | the effects of incretin based therapy on regulatory FOXP3+ T cells will be measured at baseline and after 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunophenotyping | 4 weeks | The effect of incretin based therapy on circulating immune cells and cytokine secretion at baseline and after 4 weeks |
Countries
Austria
Outcome results
None listed